|
|
|
|
LEADER |
04106nam a2200913Ia 4500 |
001 |
10.1002-npr2.12213 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 2574173X (ISSN)
|
245 |
1 |
0 |
|a Anxiety due to COVID-19 among healthcare providers during pandemic: A web-based cross-sectional survey in Iran
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/npr2.12213
|
520 |
3 |
|
|a Aim: The main purpose of this study was to assess the levels of anxiety, depression, and stress among healthcare providers in Iran. Methods: This descriptive cross-sectional survey was performed on healthcare providers selected through the convenience sampling method from April 6 to May 19, 2020, during the COVID-19 pandemic. To this end, a self-report web-based questionnaire made up of a sociodemographic characteristics information form, Depression, Anxiety, and Stress Scale (DASS), and Corona Disease Anxiety Scale (CDAS) was distributed. Descriptive statistics, chi-square test (χ2), and univariate and multivariate logistic regression models were accordingly practiced to analyze the data using the Statistical Package for Social Sciences (SPSS) software. Results: Of 1343 healthcare providers, 45.8% and 73.0% had moderate physical and psychological anxiety symptoms, respectively. The logistic regression model similarly demonstrated that anxiety caused by COVID-19 was significantly correlated with the age ranges of 41-50 (P =.007) and 51-60 (P =.014) years as well as male participants (P <.001). In addition, the prevalence rates of depression and stress were, respectively, reported by 35.1% and 27.8%. There was correspondingly a significant relationship between depression and age as well as stress and gender. Conclusions: It seems that healthcare managers need to focus more attention on psychological aspects in healthcare providers during this pandemic and plan to teach them about coping strategies. © 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a Adult
|
650 |
0 |
4 |
|a anxiety
|
650 |
0 |
4 |
|a anxiety
|
650 |
0 |
4 |
|a Anxiety
|
650 |
0 |
4 |
|a anxiety assessment
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a convenience sample
|
650 |
0 |
4 |
|a coping behavior
|
650 |
0 |
4 |
|a coronavirus
|
650 |
0 |
4 |
|a coronavirus disease 2019
|
650 |
0 |
4 |
|a COVID-19
|
650 |
0 |
4 |
|a Cross-Sectional Studies
|
650 |
0 |
4 |
|a cross-sectional study
|
650 |
0 |
4 |
|a data analysis software
|
650 |
0 |
4 |
|a dentist
|
650 |
0 |
4 |
|a depression
|
650 |
0 |
4 |
|a depression
|
650 |
0 |
4 |
|a Depression, Anxiety and Stress Scale
|
650 |
0 |
4 |
|a epidemiology
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a groups by age
|
650 |
0 |
4 |
|a health care personnel
|
650 |
0 |
4 |
|a Health Personnel
|
650 |
0 |
4 |
|a healthcare workers
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a infection
|
650 |
0 |
4 |
|a internal consistency
|
650 |
0 |
4 |
|a Internet
|
650 |
0 |
4 |
|a Internet
|
650 |
0 |
4 |
|a Iran
|
650 |
0 |
4 |
|a Iran
|
650 |
0 |
4 |
|a laboratory personnel
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a Male
|
650 |
0 |
4 |
|a medical history
|
650 |
0 |
4 |
|a medical staff
|
650 |
0 |
4 |
|a medical student
|
650 |
0 |
4 |
|a mental disease
|
650 |
0 |
4 |
|a middle aged
|
650 |
0 |
4 |
|a Middle Aged
|
650 |
0 |
4 |
|a midwife
|
650 |
0 |
4 |
|a nurse
|
650 |
0 |
4 |
|a pandemic
|
650 |
0 |
4 |
|a pandemic
|
650 |
0 |
4 |
|a Pandemics
|
650 |
0 |
4 |
|a pharmacist
|
650 |
0 |
4 |
|a physical disease
|
650 |
0 |
4 |
|a physician
|
650 |
0 |
4 |
|a physiological stress
|
650 |
0 |
4 |
|a prevalence
|
650 |
0 |
4 |
|a psychological aspect
|
650 |
0 |
4 |
|a psychology
|
650 |
0 |
4 |
|a radiologist
|
650 |
0 |
4 |
|a resident
|
650 |
0 |
4 |
|a social media
|
650 |
0 |
4 |
|a stress
|
700 |
1 |
|
|a Azizi, M.
|e author
|
700 |
1 |
|
|a Elyasi, F.
|e author
|
700 |
1 |
|
|a Ghasemian, R.
|e author
|
700 |
1 |
|
|a Hasannezad Reskati, M.
|e author
|
700 |
1 |
|
|a Kamali, M.
|e author
|
700 |
1 |
|
|a Moosazadeh, M.
|e author
|
773 |
|
|
|t Neuropsychopharmacology Reports
|